NCT02352311View on ClinicalTrials.gov

Safety and Pharmacokinetic Characteristics of DKF-313

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Benign Prostate HyperplasiaHealthy
Interventions
DRUG

DKF-313

Combination of dutasteride 0.5 mg and tadalafil 5 mg

DRUG

AVODART

Dutasteride 0.5 mg

DRUG

CIALIS

Tadalafil 5 mg

Trial Locations (1)

561-712

Chonbuk National University Hospital, Jeonju

Sponsors
All Listed Sponsors
lead

Dongkook Pharmaceutical Co., Ltd.

INDUSTRY